US expand use of Janssen’s Darzalex
The approval broadens the drug’s label to include fifth treatment option in the relapsed/refractory multiple myeloma setting
Read More
Tag: Genmab
Genmab/Janssen’s Darzalex combo hits the mark in phase 3 study
Subcutaneous formulation of Darzalex in combination with pomalidomide and dexamethasone meets primary endpoint
Read More
AbbVie and Genmab link for oncology collaboration
AbbVie will pay Genmab $750 million upfront, and potentially up to $3.15 billion in additional development, regulatory and sales milestone payments
Read More
Genmab/Novatis’ Arzerra fails to hit NHL targets
Adding Arzerra to treatment with Treanda has failed to significantly extend progression-free survival in patients with indolent B cell non-Hodgkin’s lymphoma.
Read More
US expands use of Novartis/Genmab’s Arzerra
US regulators have expanded the approved uses of Novartis/Genmab’s Arzerra so that the biologic can now be used alongside fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukaemia.
Read More
Janssen seeks to expand use of multiple myeloma drug
Janssen Biotech is seeking to expand the scope of Darzalex as a second-line combination treatment for multiple myeloma.
Read More
J&J’s Darzalex improves outcomes in multiple myeloma trial
Adding Johnson & Johnson’s Darzalex to the standard regimen of Takeda’s Velcade and dexamethasone significantly improved outcomes for patients with recurrent or refractory multiple myeloma, show findings of a late-stage trial.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
